Expertise in
10
conditions

Hirokazu Oguni

Asaka, JP 
Expertise in
10
conditions
Asaka, JP 

Overview

Hirokazu Oguni practices practicing medicine in Asaka, Japan.

Oguni is highly rated in 10 conditions, according to our data. Their clinical expertise encompasses Myoclonic Epilepsy, Generalized Tonic-Clonic Seizure, Epilepsy, and Absence Seizure.

They are actively involved in clinical research, co-authoring 67 peer reviewed articles and participating in 2 clinical trials.

Locations

Asaka, Japan
Other Locations
Tokyo, Japan
Shinjuku, 1628666, Japan
Yachiyo, Japan
Shinjiku, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings
A Phase 3, Multicenter, Open-label Extension Study of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in Community Settings
Enrollment Status: Completed
Publish Date: September 14, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room
A Phase 3, Multicenter, Open-label Study to Determine the Efficacy, Safety, and Pharmacokinetics of Buccally Administered MHOS/SHP615 in Pediatric Patients With Status Epilepticus (Convulsive) in the Hospital or Emergency Room
Enrollment Status: Completed
Publish Date: July 31, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

67 Total Publications

Epileptic seizures temporally associated with recombinant human growth hormone therapy in children: A case series of three patients.
Epileptic seizures temporally associated with recombinant human growth hormone therapy in children: A case series of three patients.
Journal: SAGE open medical case reports
Published: February 27, 2026

Frequently Asked Questions about Hirokazu Oguni

Is Hirokazu Oguni a top-rated expert for Myoclonic Epilepsy?

MediFind is an objective health platform that identifies experts based on real-world data. Hirokazu Oguni is classified as an Distinguished expert for Myoclonic Epilepsy, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hirokazu Oguni participate in research or clinical trials?

Yes. Hirokazu Oguni has published 67 articles and abstracts on conditions like Myoclonic Epilepsy. You can view a list of Hirokazu Oguni's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Oguni's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 18 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile